Get the Stockscreener App
7.27
0.68%
-0.05
After Hours:
7.35
0.08
+1.10%
Vanda Pharmaceuticals Inc stock is traded at $7.27, with a volume of 861.42K.
It is down -0.68% in the last 24 hours and down -17.48% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$7.32
Open:
$7.3
24h Volume:
861.42K
Relative Volume:
0.38
Market Cap:
$429.72M
Revenue:
$216.11M
Net Income/Loss:
$-220.47M
P/E Ratio:
-1.9458
EPS:
-3.7363
Net Cash Flow:
$-110.44M
1W Performance:
-0.27%
1M Performance:
-17.48%
6M Performance:
+35.13%
1Y Performance:
+66.36%
1-Day Range:
$7.20
$7.40
1-Week Range:
$7.0597
$7.42
52-Week Range:
$3.8092
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
7.27 | 432.67M | 216.11M | -220.47M | -110.44M | -3.7363 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-26 | Initiated | Truist | Buy |
| Nov-05-25 | Initiated | B. Riley Securities | Buy |
| Oct-31-24 | Initiated | H.C. Wainwright | Buy |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Scott Laverne Howell Net Worth (2026) - GuruFocus
Polymeropoulos Christos Vasilios Mihael Net Worth (2026) - GuruFocus
Vanda Pharmaceuticals (NASDAQ: VNDA) executive details stock, options and RSUs - Stock Titan
[Form 3] Vanda Pharmaceuticals Inc. Initial Statement of Beneficial Ownership - Stock Titan
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
Vanda Pharmaceuticals (VNDA) Criticizes FDA Review Process Changes - GuruFocus
Market Leaders: Should I invest in Vanda Pharmaceuticals Inc before earnings2026 Top Gainers & Technical Confirmation Alerts - baoquankhu1.vn
Vanda Pharmaceuticals opposes FDA drug review timeline proposal - Investing.com
Vanda Pharmaceuticals opposes FDA drug review timeline proposal By Investing.com - Investing.com India
A 180-day drug review rule could stretch to 10-12 months under FDA plan - Stock Titan
Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News, Quote & History - Yahoo! Finance Canada
H.C. Wainwright reiterates Vanda Pharmaceuticals stock rating on GLP-1 trial - Investing.com Australia
Vanda initiates trial of NEREUS for GLP-1 therapy side effects By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals (VNDA) Launches Thetis Trial for Vomiting Prevention - GuruFocus
Vanda initiates trial of NEREUS for GLP-1 therapy side effects - Investing.com Australia
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - Finviz
Vanda Pharmaceuticals Announces Initiation Of The Thetis Study, A Clinical Trial Of Nereus™ For The Prevention Of Vomiting Induced By Glp-1 Receptor Agonists - TradingView — Track All Markets
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - Nasdaq
Options Flow: What is the target price for Vanda Pharmaceuticals Inc stockWeekly Trend Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Rate Cut: Is Vanda Pharmaceuticals Inc affected by consumer sentimentStop Loss & Consistent Income Trade Recommendations - baoquankhu1.vn
Downgrade Watch: Can Vanda Pharmaceuticals Inc ride the EV waveDip Buying & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Vanda Announces Resignation of Senior Legal Executive - The Globe and Mail
Vanda Pharmaceuticals executive Timothy Williams to resign as general counsel - Investing.com Australia
Timothy Williams resigns as Senior Vice President, General Counsel and Secretary at Vanda - TradingView — Track All Markets
Vanda Pharmaceuticals Inc. Announces Resignation of Timothy Williams as Senior Vice President, General Counsel and Secretary, Effective April 10, 2026 - marketscreener.com
Vanda Pharmaceuticals (NASDAQ: VNDA) general counsel resigns role - Stock Titan
Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Aug Levels: Can Vanda Pharmaceuticals Inc ride the EV wavePortfolio Return Report & Low Risk Investment Opportunities - baoquankhu1.vn
Pullback Watch: Will Vanda Pharmaceuticals Inc outperform tech stocksRate Cut & Reliable Momentum Entry Alerts - baoquankhu1.vn
VNDA Technical Analysis & Stock Price Forecast - Intellectia AI
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Update - MarketBeat
Vanguard disaggregates holdings; reports 0 shares of Vanda Pharmaceuticals (VNDA) - Stock Titan
Truist reiterates Vanda Pharmaceuticals stock rating after EMA decision By Investing.com - Investing.com Canada
Vanda Pharmaceuticals stock faces institutional dominance amid biotech sector volatility and retail - AD HOC NEWS
Gastroparesis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma - Barchart
Gastroparesis Pipeline 2026: FDA Updates, Therapy - openPR.com
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to S&P Biotechnology Select Industry Index - MarketScreener
Vanda Pharmaceuticals Faces New Market Challenges Amid Share Sale and Regulatory Roadblocks - timothysykes.com
If You Invested $1,000 in Vanda Pharma (VNDA) - Stock Titan
Insider Sell: Can Vanda Pharmaceuticals Inc ride the EV wave2026 PostEarnings & Intraday High Probability Setup Alerts - baoquankhu1.vn
CEO’s Significant Stock Sale Raises Concerns for Vanda Pharmaceuticals - timothysykes.com
Vanda Pharmaceuticals Faces Shareholder Movements and Regulatory Setbacks - StocksToTrade
Vanda Pharmaceuticals Inc. (VNDA) latest stock news and headlines - Yahoo Finance Singapore
Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti for bipolar, schizophrenia - MSN
Vanda Pharmaceuticals Raises Concerns Over FDA's New Guidance on Drug Development - Intellectia AI
VNDA Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
What's going on with Vanda Pharma stock Tuesday? - MSN
Vanda Pharmaceuticals Faces Setbacks as CEO Mihael Polymeropoulos Sells Shares - StocksToTrade
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerat - GuruFocus
Vanda Pharmaceuticals urges FDA to accelerate move away from animal testing - Traders Union
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):